<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262041</url>
  </required_header>
  <id_info>
    <org_study_id>V59P6</org_study_id>
    <secondary_id>BB-IND 11278</secondary_id>
    <nct_id>NCT00262041</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents</brief_title>
  <official_title>A Phase 2, Randomized, Single-blind, Controlled, Multicenter Study to Compare the Safety and Immune Response of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With the Safety and Immune Response of One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Adolescents 11 to 17 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of Novartis
      Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide
      vaccine administered to healthy adolescents ages 11 to 17 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date>March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With N.Meningitidis Human Serum Bactericidal Activity (hSBA) Titers≥ 1:4, After One Dose of Either MenACWY-CRM Vaccine, With Adjuvant or Without Adjuvant, or MenACWY-PS Vaccine</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Immune response of a single dose of MenACWY-CRM conjugate vaccine, with adjuvant or without adjuvant compared to that of one dose of MenACWY polysaccharide (PS) vaccine, one month after administration to subjects aged 11 to 17 years, as measured by the percentage of subjects with hSBA titers &gt;1:4 directed against N meningitidis serogroups A, C, W and Y</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers (GMT) After One Dose Of MenACWY-CRM Vaccine, With Adjuvant or Without Adjuvant or MenACWY-PS Vaccine</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Immune response of one dose of MenACWY-CRM conjugate vaccine, with adjuvant or without adjuvant or MenACWY-PS vaccine, one month after administration in subjects 11 to 17 years of age, as measured by hSBA geometric mean titers (GMTs) against N meningitidis serogroups A, C, W, and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Titers≥ 1:4, After One Dose Of Either MenACWY-CRM(Ad-) or MenACWY-PS Vaccine</measure>
    <time_frame>12 months after vaccination</time_frame>
    <description>Immune response of one dose of MenACWY-CRM(Ad-) compared to that of one dose of MenACWY polysaccharide(MenACWY-PS) vaccine, 12 months after administration to subjects aged 11 to 17 years, as measured by the percentage of subjects with human complement serum bactericidal activity (hSBA) titers≥1:4 against N meningitidis serogroups A, C, W, and Y. The endpoint point compares only data of unadjuvanted formulation of the conjugate vaccine to the polysaccharide vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers (GMT) After One Dose Of Either MenACWY-CRM(Ad-) or MenACWY-PS Vaccine</measure>
    <time_frame>12 months after vaccination</time_frame>
    <description>Immune response of one dose of MenACWY-CRM(Ad-) conjugate vaccine compared with that of MenACWY-PS vaccine, 12 months after administration in subjects 11 to 17 years of age, as measured by hSBA geometric mean titers (GMTs) against N meningitidis serogroups A, C, W, and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of Subjects 11 to 17 Years of Age Who Reported Solicited Local and Systemic Adverse Events After the Vaccination</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Safety was assessed as the number of subjects 11 to 17 years of age who reported solicited local and systemic adverse events from day 1 up to and including day 7 after the vaccination of either MenACWY-CRM conjugate vaccine, with adjuvant or without adjuvant or MenACWY-PS vaccine.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">524</enrollment>
  <condition>Prevention of Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>MenACWY-CRM(Ad+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one single dose of adjuvanted formulation of conjugate vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY-CRM(Ad-)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY- PS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received one single dose of the polysaccharide vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM conjugate vaccine, adjuvanted</intervention_name>
    <arm_group_label>MenACWY-CRM(Ad+)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM conjugate vaccine, unadjuvanted</intervention_name>
    <arm_group_label>MenACWY-CRM(Ad-)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY polysaccharide vaccine</intervention_name>
    <arm_group_label>MenACWY- PS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adolescents between and including 11-17 years of age, who provide written
             informed consent

        Exclusion Criteria:

          -  Subjects with a previous or suspected disease caused by N. meningitidis; or previous
             immunization with a meningococcal vaccine or vaccine containing meningococcal
             antigen(s); Any serious acute, chronic or progressive disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009 Feb;28(2):86-91. doi: 10.1097/INF.0b013e31818a0237.</citation>
    <PMID>19116603</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2005</study_first_submitted>
  <study_first_submitted_qc>December 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <results_first_submitted>September 9, 2013</results_first_submitted>
  <results_first_submitted_qc>September 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2013</results_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at Seattle, Washington; Pittsburgh, Pennsylvania; Rochester, Minnesota.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenACWY-CRM(Ad+)</title>
          <description>Subjects received one single dose of adjuvanted formulation of conjugate vaccine.</description>
        </group>
        <group group_id="P2">
          <title>MenACWY-CRM(Ad-)</title>
          <description>Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.</description>
        </group>
        <group group_id="P3">
          <title>MenACWY-PS</title>
          <description>Subjects received one single dose of the MenACWY polysaccharide vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="147"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MenACWY-CRM(Ad+)</title>
          <description>Subjects received one single dose of adjuvanted formulation of conjugate vaccine.</description>
        </group>
        <group group_id="B2">
          <title>MenACWY-CRM(Ad-)</title>
          <description>Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.</description>
        </group>
        <group group_id="B3">
          <title>MenACWY-PS - Stage 1</title>
          <description>Subjects received a single of MenACWY polysaccharide vaccine on day 1 (Stage 1 - 1:1 randomization scheme).</description>
        </group>
        <group group_id="B4">
          <title>MenACWY-PS -Stage 2</title>
          <description>Subjects received a single dose of MenACWY polysaccharide vaccine (Stage 2 - 4:1 MenACWY-CRM:MenACWY-PS randomization scheme).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="170"/>
            <count group_id="B4" value="39"/>
            <count group_id="B5" value="524"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.3" spread="1.9"/>
                    <measurement group_id="B2" value="14.1" spread="1.8"/>
                    <measurement group_id="B3" value="14.2" spread="1.8"/>
                    <measurement group_id="B4" value="14.2" spread="2.0"/>
                    <measurement group_id="B5" value="14.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With N.Meningitidis Human Serum Bactericidal Activity (hSBA) Titers≥ 1:4, After One Dose of Either MenACWY-CRM Vaccine, With Adjuvant or Without Adjuvant, or MenACWY-PS Vaccine</title>
        <description>Immune response of a single dose of MenACWY-CRM conjugate vaccine, with adjuvant or without adjuvant compared to that of one dose of MenACWY polysaccharide (PS) vaccine, one month after administration to subjects aged 11 to 17 years, as measured by the percentage of subjects with hSBA titers &gt;1:4 directed against N meningitidis serogroups A, C, W and Y</description>
        <time_frame>1 month after vaccination</time_frame>
        <population>Analysis was done on the per-protocol population i.e all subjects who received all the relevant doses of vaccine correctly, and provided evaluable serum samples at the relevant time points, and had no major protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM(Ad+)</title>
            <description>Subjects received one single dose of adjuvanted formulation of conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM(Ad-)</title>
            <description>Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-PS</title>
            <description>Subjects received one single dose of the MenACWY polysaccharide vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With N.Meningitidis Human Serum Bactericidal Activity (hSBA) Titers≥ 1:4, After One Dose of Either MenACWY-CRM Vaccine, With Adjuvant or Without Adjuvant, or MenACWY-PS Vaccine</title>
          <description>Immune response of a single dose of MenACWY-CRM conjugate vaccine, with adjuvant or without adjuvant compared to that of one dose of MenACWY polysaccharide (PS) vaccine, one month after administration to subjects aged 11 to 17 years, as measured by the percentage of subjects with hSBA titers &gt;1:4 directed against N meningitidis serogroups A, C, W and Y</description>
          <population>Analysis was done on the per-protocol population i.e all subjects who received all the relevant doses of vaccine correctly, and provided evaluable serum samples at the relevant time points, and had no major protocol violation.</population>
          <units>Percentages Of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA (N=158,148,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="80" upper_limit="92"/>
                    <measurement group_id="O2" value="84" lower_limit="77" upper_limit="89"/>
                    <measurement group_id="O3" value="46" lower_limit="38" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC (N=161,148,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="87" upper_limit="96"/>
                    <measurement group_id="O2" value="88" lower_limit="81" upper_limit="93"/>
                    <measurement group_id="O3" value="71" lower_limit="64" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW (N=161,146,173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="95" lower_limit="90" upper_limit="98"/>
                    <measurement group_id="O3" value="88" lower_limit="83" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY (N=159, 147,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O2" value="96" lower_limit="91" upper_limit="98"/>
                    <measurement group_id="O3" value="84" lower_limit="77" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate non-inferiority of percentages of subjects with hSBA titer ≥ 1:4 who received MenACWY Ad+ vaccine group against serogroup A compared with that of MenACWY PS vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of MenACWY Ad+ vaccine against the serogroup A was assessed to that of the MenACWY PS vaccine if the lower limit of the two-sided 95% CI around the difference in proportions was greater than -10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate non-inferiority of percentages of subjects with hSBA titer ≥ 1:4 who received MenACWY Ad- vaccine group against serogroup A compared with that of MenACWY PS vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of MenACWY Ad- vaccine against the serogroup A was assessed to that of the MenACWY PS vaccine if the lower limit of the two-sided 95% CI around the difference in proportions was greater than -10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate non-inferiority of percentages of subjects with hSBA titer ≥ 1:4 who received MenACWY Ad+ vaccine group against serogroup C compared with that of MenACWY PS vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of MenACWY Ad+ vaccine against the serogroup C was assessed to that of the MenACWY PS vaccine if the lower limit of the two-sided 95% CI around the difference in proportions was greater than -10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate non-inferiority of percentages of subjects with hSBA titer ≥ 1:4 who received MenACWY Ad- vaccine group against serogroup C compared with that of MenACWY PS vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of MenACWY Ad- vaccine against the serogroup C was assessed to that of the MenACWY PS vaccine if the lower limit of the two-sided 95% CI around the difference in proportions was greater than -10%.</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate non-inferiority of percentages of subjects with hSBA titer ≥ 1:4 who received MenACWY Ad+ vaccine group against serogroup W compared with that of MenACWY PS vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of MenACWY Ad+ vaccine against the serogroup W was assessed to that of the MenACWY PS vaccine if the lower limit of the two-sided 95% CI around the difference in proportions was greater than -10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate non-inferiority of percentages of subjects with hSBA titer ≥ 1:4 who received MenACWY Ad- vaccine group against serogroup W compared with that of MenACWY PS vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of MenACWY Ad- vaccine against the serogroup W was assessed to that of the MenACWY PS vaccine if the lower limit of the two-sided 95% CI around the difference in proportions was greater than -10%.</non_inferiority_desc>
            <p_value>0.071</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate non-inferiority of percentages of subjects with hSBA titer ≥ 1:4 who received MenACWY Ad+ vaccine group against serogroup Y compared with that of MenACWY PS vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of MenACWY Ad+ vaccine against the serogroup Y was assessed to that of the MenACWY PS vaccine if the lower limit of the two-sided 95% CI around the difference in proportions was greater than -10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To demonstrate non-inferiority of percentages of subjects with hSBA titer ≥ 1:4 who received MenACWY Ad- vaccine group against serogroup Y compared with that of MenACWY PS vaccine.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of MenACWY Ad- vaccine against the serogroup Y was assessed to that of the MenACWY PS vaccine if the lower limit of the two-sided 95% CI around the difference in proportions was greater than -10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titers (GMT) After One Dose Of MenACWY-CRM Vaccine, With Adjuvant or Without Adjuvant or MenACWY-PS Vaccine</title>
        <description>Immune response of one dose of MenACWY-CRM conjugate vaccine, with adjuvant or without adjuvant or MenACWY-PS vaccine, one month after administration in subjects 11 to 17 years of age, as measured by hSBA geometric mean titers (GMTs) against N meningitidis serogroups A, C, W, and Y.</description>
        <time_frame>1 month after vaccination</time_frame>
        <population>Analysis was done on per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM(Ad+)</title>
            <description>Subjects received one single dose of adjuvanted formulation of conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM(Ad-)</title>
            <description>Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-PS</title>
            <description>Subjects received one single dose of the MenACWY polysaccharide vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titers (GMT) After One Dose Of MenACWY-CRM Vaccine, With Adjuvant or Without Adjuvant or MenACWY-PS Vaccine</title>
          <description>Immune response of one dose of MenACWY-CRM conjugate vaccine, with adjuvant or without adjuvant or MenACWY-PS vaccine, one month after administration in subjects 11 to 17 years of age, as measured by hSBA geometric mean titers (GMTs) against N meningitidis serogroups A, C, W, and Y.</description>
          <population>Analysis was done on per-protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA (N=158, 148, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="26" upper_limit="43"/>
                    <measurement group_id="O2" value="34" lower_limit="26" upper_limit="44"/>
                    <measurement group_id="O3" value="6.97" lower_limit="5.51" upper_limit="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC (N=161, 148, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="48" upper_limit="100"/>
                    <measurement group_id="O2" value="58" lower_limit="39" upper_limit="85"/>
                    <measurement group_id="O3" value="30" lower_limit="22" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW (161, 146, 173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="49" upper_limit="75"/>
                    <measurement group_id="O2" value="49" lower_limit="39" upper_limit="62"/>
                    <measurement group_id="O3" value="30" lower_limit="24" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY (159,147,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" lower_limit="85" upper_limit="147"/>
                    <measurement group_id="O2" value="100" lower_limit="75" upper_limit="133"/>
                    <measurement group_id="O3" value="34" lower_limit="27" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Titers≥ 1:4, After One Dose Of Either MenACWY-CRM(Ad-) or MenACWY-PS Vaccine</title>
        <description>Immune response of one dose of MenACWY-CRM(Ad-) compared to that of one dose of MenACWY polysaccharide(MenACWY-PS) vaccine, 12 months after administration to subjects aged 11 to 17 years, as measured by the percentage of subjects with human complement serum bactericidal activity (hSBA) titers≥1:4 against N meningitidis serogroups A, C, W, and Y. The endpoint point compares only data of unadjuvanted formulation of the conjugate vaccine to the polysaccharide vaccine.</description>
        <time_frame>12 months after vaccination</time_frame>
        <population>Analysis was done on PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM(Ad-)</title>
            <description>Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS</title>
            <description>Subjects received one single dose of the MenACWY polysaccharide vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With hSBA Titers≥ 1:4, After One Dose Of Either MenACWY-CRM(Ad-) or MenACWY-PS Vaccine</title>
          <description>Immune response of one dose of MenACWY-CRM(Ad-) compared to that of one dose of MenACWY polysaccharide(MenACWY-PS) vaccine, 12 months after administration to subjects aged 11 to 17 years, as measured by the percentage of subjects with human complement serum bactericidal activity (hSBA) titers≥1:4 against N meningitidis serogroups A, C, W, and Y. The endpoint point compares only data of unadjuvanted formulation of the conjugate vaccine to the polysaccharide vaccine.</description>
          <population>Analysis was done on PP population.</population>
          <units>Percentages Of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA (N=140, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="28" upper_limit="44"/>
                    <measurement group_id="O2" value="44" lower_limit="36" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC (N=140, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="79" upper_limit="91"/>
                    <measurement group_id="O2" value="69" lower_limit="61" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW (N=138, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90" upper_limit="98"/>
                    <measurement group_id="O2" value="72" lower_limit="63" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY (N=139, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="80" upper_limit="92"/>
                    <measurement group_id="O2" value="63" lower_limit="54" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titers (GMT) After One Dose Of Either MenACWY-CRM(Ad-) or MenACWY-PS Vaccine</title>
        <description>Immune response of one dose of MenACWY-CRM(Ad-) conjugate vaccine compared with that of MenACWY-PS vaccine, 12 months after administration in subjects 11 to 17 years of age, as measured by hSBA geometric mean titers (GMTs) against N meningitidis serogroups A, C, W, and Y.</description>
        <time_frame>12 months after vaccination</time_frame>
        <population>Analysis was done on PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM(Ad-)</title>
            <description>Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS</title>
            <description>Subjects received one single dose of the MenACWY polysaccharide vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titers (GMT) After One Dose Of Either MenACWY-CRM(Ad-) or MenACWY-PS Vaccine</title>
          <description>Immune response of one dose of MenACWY-CRM(Ad-) conjugate vaccine compared with that of MenACWY-PS vaccine, 12 months after administration in subjects 11 to 17 years of age, as measured by hSBA geometric mean titers (GMTs) against N meningitidis serogroups A, C, W, and Y.</description>
          <population>Analysis was done on PP population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MenA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" lower_limit="3.35" upper_limit="5.38"/>
                    <measurement group_id="O2" value="5.65" lower_limit="4.54" upper_limit="7.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenC (N=140, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="19" upper_limit="41"/>
                    <measurement group_id="O2" value="26" lower_limit="18" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenW (N=138, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="31" upper_limit="52"/>
                    <measurement group_id="O2" value="17" lower_limit="13" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenY (N=139, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="22" upper_limit="41"/>
                    <measurement group_id="O2" value="13" lower_limit="9.49" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers of Subjects 11 to 17 Years of Age Who Reported Solicited Local and Systemic Adverse Events After the Vaccination</title>
        <description>Safety was assessed as the number of subjects 11 to 17 years of age who reported solicited local and systemic adverse events from day 1 up to and including day 7 after the vaccination of either MenACWY-CRM conjugate vaccine, with adjuvant or without adjuvant or MenACWY-PS vaccine.</description>
        <time_frame>Day 1 to Day 7</time_frame>
        <population>Analysis was done on safety dataset - subjects who received at least one study dose and had Post baseline safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM(Ad+)</title>
            <description>Subjects received one single dose of adjuvanted formulation of conjugate vaccine.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS - Stage 1</title>
            <description>Subjects received a single of MenACWY polysaccharide vaccine on day 1 (Stage 1)</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM(Ad-)</title>
            <description>Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.</description>
          </group>
          <group group_id="O4">
            <title>MenACWY-PS -Stage 2</title>
            <description>Subjects received a single dose of MenACWY polysaccharide vaccine (Stage 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Subjects 11 to 17 Years of Age Who Reported Solicited Local and Systemic Adverse Events After the Vaccination</title>
          <description>Safety was assessed as the number of subjects 11 to 17 years of age who reported solicited local and systemic adverse events from day 1 up to and including day 7 after the vaccination of either MenACWY-CRM conjugate vaccine, with adjuvant or without adjuvant or MenACWY-PS vaccine.</description>
          <population>Analysis was done on safety dataset - subjects who received at least one study dose and had Post baseline safety data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="107"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 38°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic Med Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed home Due to a reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All solicited adverse events (AEs) were collected upto day 7 after each vaccination.</time_frame>
      <desc>All AEs through day 7 and/or all serious adverse events (SAEs) and/or AEs requiring a physician visit and/or resulting in premature withdrawal from the study from day 1 to study termination (day 360).</desc>
      <group_list>
        <group group_id="E1">
          <title>MenACWY-CRM(Ad+)</title>
          <description>Subjects received one single dose of adjuvanted formulation of conjugate vaccine.</description>
        </group>
        <group group_id="E2">
          <title>MenACWY-CRM(Ad-)</title>
          <description>Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.</description>
        </group>
        <group group_id="E3">
          <title>MenACWY-PS - Stage 1</title>
          <description>Subjects received a single of MenACWY polysaccharide vaccine on day 1 (Stage 1 - 1:1 randomization scheme).</description>
        </group>
        <group group_id="E4">
          <title>MenACWY-PS -Stage 2</title>
          <description>Subjects received a single dose of MenACWY polysaccharide vaccine (Stage 2 - 4:1 MenACWY-CRM:MenACWY-PS randomization scheme).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cellulitis Pharyngeal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arachnoid Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination, Auditory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="170"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

